Apart from ibrutinib, people with M-CLL, devoid of TP53 aberrations and in good shape more than enough to tolerate FCR therapy, should still be very good candidates for your latter, Together with the reward staying this treatment method might be finished in six months when ibrutinib has to be taken indefinitely. This option could well be specially